Empagliflozin Production Cost Reports

The report provides a detailed analysis essential for establishing an Empagliflozin manufacturing plant. It encompasses all critical aspects necessary for Empagliflozin production, including the cost of Empagliflozin production, Empagliflozin plant cost, Empagliflozin production costs, and the overall Empagliflozin manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Empagliflozin production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Empagliflozin is basically used in the treatment of type 2 diabetes. It works by increasing urinary glucose excretion so as to decrease renal reabsorption of glucose and improve glycemic control. It is available both alone and in fixed-dose combinations with other antidiabetic agents like metformin and linagliptin. Empagliflozin has been shown to decrease cardiovascular death and hospitalization for heart failure among patients with type 2 diabetes who have known atherosclerotic cardiovascular disease. It is also approved for patients with chronic kidney disease progression. It is highly selective at inhibiting SGLT2 as opposed to SGLT1 and demonstrates meaningful evidence supporting potential benefits in diabetes care along with benefits in the reduction of cardiovascular disease risk.

The market of Empagliflozin is driven by several factors. Its growing use in the treatment of type 2 diabetes contributes to its increasing demand. Its use in maintaining cardiovascular health, especially in those people with Type 2 and heart complications, makes it a sought-after medication. Its use as a personalized medicine and its efficacy makes it an option for a wider range of patients at different stages of their diabetes management. It is cost-effectiveness in dual benefits of glycaemic control and cardiovascular risk reduction with one medicine further contributes to its demand. Thus, industrial empagliflozin procurement is influenced by its growing use in treating type 2 diabetes and maintaining cardiovascular health, along with providing personalized and cost-effective care and expanding indications for use in a wider range of patients.

Raw Material for Empagliflozin Production

According to the Empagliflozin manufacturing plant project report, the key raw materials used in the production of Empagliflozin include Benzoic Acid Derivative-Glucose Derivative-Tetrahydrofuran-Triethyl Silane-Aluminium Chloride.

Manufacturing Process of Empagliflozin

The extensive Empagliflozin production cost report consists of the following major industrial manufacturing process:

• From Benzoic Acid Derivative, Glucose Derivative, Tetrahydrofuran, Triethyl Silane, and Aluminium Chloride: The manufacturing process for Empagliflozin has several steps. First, the substituted benzoic acid derivative is used to form an intermediate. After that, this intermediate is reacted with a glucose derivative in tetrahydrofuran at low temperatures. This product is deprotected and further reacted with triethyl silane and aluminum chloride, forming Empagliflozin. Finally, the product is purified to obtain pure Empagliflozin.

Empagliflozin is white to yellow in color. Its molecular formula is C23H27ClO7, and it has a molecular weight of around 450.91 g/mol. It is very faintly soluble in water, sparingly soluble in methanol, and slightly soluble in ethanol and acetonitrile. It shows no polymorphism, and it has a partition coefficient value of 1.7. It is sensitive to thermal and photolytic conditions and is less stable in basic and oxidative environments. It has a high protein binding rate of around 86.2% in plasma and has low metabolism, mainly through glucuronidation. All these notable physical and chemical properties contribute to its therapeutic application in managing type 2 diabetes.